 |
| Once its deal with Boston Scientific is nixed, Terumo will market devices like the Glidewire on its own in the U.S.--Courtesy of Terumo |
Terumo is striking out on its own in the urology market, announcing that it will terminate its distribution deal with Boston Scientific ($BSX) and take on U.S. sales of its Glidewire Hydrophilic Guidewire products.
The U.S. urology market is poised to reach $2.3 billion by 2016, Terumo says, and Glidewire is the market leader, used in about one-third of all minimally invasive urological procedures in the country. Come April 1, Terumo will take up Boston Scientific's former job of direct sales, marketing, support and distribution for the devices, helping it better cash in on a swelling market.
With its January acquisition of sheath-maker Onset Medical, Terumo now has the technology and capacity to expand its urology market share, segment president James Rushworth said.
"We are poised to offer innovative access systems to the urology specialty and intend to leverage world-class technology with our existing robust distribution, supply, and service capabilities to forge strong physician relationships," Rushworth said in a statement.
Terumo is no stranger to distribution partnerships. Earlier this month, the company struck up a deal with Switzerland's Biosensors International to promote its Nobori drug-eluting stent in its home country of Japan, and Terumo had a similar arrangement with Boston Scientific to distribute its cardiac devices, but the company backed out of that one in 2006, Bloomberg notes.
- read Terumo's announcement
- check out Bloomberg's story